|
GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma
Genetic Engineering News GlaxoSmithKline (GSK) and Theravance are reporting mostly positive results from two studies for Relovair in chronic obstructive pulmonary disease (COPD) and asthma. Relovair met its primary endpoint in one of two replicate studies in COPD comparing it … GSK and Theravance Announce Completion of the Relovair(TM)* Registrational … GSK lung drug has mixed results but filing on track GSK's Relovair on track for COPD drug filing; talks on asthma in US ongoing |
View full post on asthma – Google News